The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index; 11 of the 19 sources its claims cite were checked for support.
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial
Open accessAbstract
BACKGROUND: The SELECT trial found semaglutide reduced major adverse cardiovascular events (MACE) in patients with overweight or obesity with cardiovascular disease but without diabetes. We report a prespecified analysis of the SELECT trial on the relationships between baseline adiposity measures, treatment-induced adiposity changes, and subsequent MACE risk. METHODS: were enrolled in 41 countries (804 sites) and randomised 1:1 to once-weekly semaglutide 2·4 mg or placebo. The primary outcome was time to first MACE (composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke). Adiposity measures included weight and waist circumference. In this analysis, risk of MACE occurring after 20 weeks was assessed between patients by adiposity changes in the first 20 weeks and, in a separate analysis, all in-trial MACE were assessed between patients by adiposity changes over 104 weeks. This trial is registered with ClinicalTrials.gov, NCT03574597. FINDINGS: Semaglutide significantly reduced MACE incidence compared with placebo among 17 604 patients enrolled in SELECT, with consistent benefits across all baseline weight and waist circumference categories. In the semaglutide group, analyses for linear trends showed lower baseline bodyweight and waist circumference were associated with lower incidence of MACE-an average 4% reduction in risk per 5 kg lower bodyweight (hazard ratio [HR] 0·96 [95% CI 0·94-0·99]; p=0·001) and per 5 cm smaller waist circumference (0·96 [0·93-0·99]; p=0·004). In the placebo group, lower baseline waist circumference (0·96 [0·94-0·99]; p=0·007), but not bodyweight (0·99 [0·97-1·01]; p=0·28), was associated with a lower MACE risk and weight loss was paradoxically associated with increased MACE risk. In those receiving semaglutide there was no linear trend linking weight loss at week 20 to subsequent MACE risk, but greater waist circumference reduction at week 20 was associated with lower subsequent MACE risk, and waist circumference reduction by week 104 was associated with lower in-trial risk of MACE. An estimated 33% of the observed benefit on MACE was mediated through waist circumference reduction (HR 0·86 [95% CI 0·77-0·97] after adjustment for time-varying changes in waist circumference). INTERPRETATION: The cardioprotective effects of semaglutide were independent of baseline adiposity and weight loss and had only a small association with waist circumference, suggesting some mechanisms for benefit beyond adiposity reduction. FUNDING: Novo Nordisk.
Overview
CoChat Summary
## TL;DR
This prespecified analysis of SELECT found that semaglutide’s cardiovascular benefit was consistent across baseline adiposity levels and was not explained by early weight loss. Waist circumference change was more closely related to MACE than bodyweight change, but accounted for only about 33% of the treatment benefit.
## Key findings
- In SELECT, semaglutide reduced MACE in 17,604 patients with overweight/obesity and established cardiovascular disease without diabetes, with benefits consistent across baseline weight and waist circumference categories.
- Among semaglutide-treated patients, lower baseline bodyweight and waist circumference were associated with lower MACE risk: about 4% lower risk per 5 kg lower bodyweight (HR 0.96, 95% CI 0.94–0.99; p=0.001) and 4% lower risk per 5 cm smaller waist circumference (HR 0.96, 95% CI 0.93–0.99; p=0.004).
- In the placebo group, lower baseline waist circumference—but not bodyweight—was associated with lower MACE risk (HR 0.96, 95% CI 0.94–0.99; p=0.007), and weight loss was paradoxically associated with higher MACE risk.
- Early weight loss at week 20 did not predict later cardiovascular benefit in the semaglutide group, whereas greater waist circumference reduction did; waist circumference reduction was estimated to mediate or mark 33% of semaglutide’s MACE benefit (HR 0.86, 95% CI 0.77–0.97 after adjustment for time-varying waist circumference).
## Methods
- Prespecified analysis of the SELECT randomized, double-blind, multicentre, placebo-controlled phase 3 trial conducted in 41 countries (804 sites); participants were aged ≥45 years, had BMI ≥27 kg/m², established atherosclerotic cardiovascular disease, and no diabetes.
- Participants were randomized 1:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo; bodyweight and waist circumference were repeatedly measured during follow-up.
- Primary analysis evaluated time-to-first MACE (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) using Cox models, including landmark analyses at 20 weeks and an in-trial analysis through 104 weeks; missing data were multiply imputed under missing-at-random assumptions.
## Limitations
- The authors state that, although the trial was conducted in 41 countries, the population was predominantly White and male, which may limit generalisability.
- The authors state that analyses of MACE by post-randomisation changes in weight or waist circumference are subject to confounding and cannot prove causation or define mechanisms.
- The authors note that the week-20 analyses did not use the earliest observed differences in MACE between treatment groups, and the week-104 cumulative-change analyses cannot account for the timing of changes in adiposity relative to MACE.
- Evident from the text: the study relied on waist circumference and bodyweight rather than direct body-composition measures, and the authors note future studies should include formal measures of body composition.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Valid · 1 Not valid · 7 Not checked · 68 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“It demonstrated that semaglutide resulted in an 8•51% percentage points mean placebo-adjusted weight reduction and a 20% reduction in MACE. 1”
§ Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial > Introduction
What the sources say
- Supportedcites [1] Lincoff, 2023, Semaglutide and cardiovascular outcomes in obesity without diabetes, N Engl J Med source
The Efficacy End Points section reports a hazard ratio of 0.80 for the primary composite cardiovascular endpoint with semaglutide versus placebo, corresponding to a 20% relative reduction in major adverse cardiovascular events in this trial. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“It demonstrated that semaglutide resulted in an 8•51% percentage points mean placebo-adjusted weight reduction and a 20% reduction in MACE. 1”
§ Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial > Introduction
What the sources say
- Supportedcites [1] Lincoff, 2023, Semaglutide and cardiovascular outcomes in obesity without diabetes, N Engl J Med source
The Body Weight and Other End Points section reports a mean weight change at 104 weeks of −9.39% with semaglutide versus −0.88% with placebo, an estimated difference of −8.51 percentage points. The Efficacy End Points section also reports a hazard ratio of 0.80 for the primary cardiovascular end point, consistent with the sentence’s 20% MACE reduction. (LLM, conf=0.95)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The SELECT trial found semaglutide reduced major adverse cardiovascular events (MACE) in patients with overweight or obesity with cardiovascular disease but without diabetes.”
§ Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial > Abstract
What the sources say
- Supportedcites [1] Lincoff, 2023, Semaglutide and cardiovascular outcomes in obesity without diabetes, N Engl J Med source
The Conclusions state that, in patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, semaglutide reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke compared with placebo. The Discussion identifies this as the SELECT trial and reports a 20% reduction in that composite outcome. (LLM, conf=0.95)
plainstates a causen = 604- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The SELECT trial, including 17 604 participants, was the largest study of GLP-1RA therapy in patients with established cardiovascular disease and elevated BMI (≥27 kg/m²) who did not have diabetes.”
§ Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial > Introduction
What the sources say
- Partly supportedcites [1] Lincoff, 2023, Semaglutide and cardiovascular outcomes in obesity without diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
The Discussion (page not provided in our copy) reports 17,604 participants with established cardiovascular disease, BMI ≥27, and no diabetes, treated with semaglutide, a GLP-1 receptor agonist. The copy does not establish the comparative claim that SELECT was the largest such study (searched: “largest” and the study description). (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The primary analysis of SELECT showed no interaction between sex, age, region, race, ethnicity, BMI, cardiovascular disease, history of heart failure, estimated glomerular filtration rate, or HbA₁ c , and treatment effect of semaglutide. 1”
§ Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial > Results
What the sources say
- Partly supportedcites [1] Lincoff, 2023, Semaglutide and cardiovascular outcomes in obesity without diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
The Efficacy End Points section reports that semaglutide’s effect on the primary end point appeared similar across all prespecified subgroups. Our copy does not identify those subgroups as the ten listed in the claim or report interaction tests for each, so the specific assertion of no interaction is not fully supported. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
45 more claims
Create a free account to see all 85 claims and to verify the 4 references still open.
- Probably not a substantial claim. 16
- It may state two separate claims as one. 24
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“mediation analyses suggest that associated improvements in glycemia, blood pressure, and lipid profile account for only a fraction of the observed cardiovascular effect”
From Weight maintenance after discontinuation of GLP-1 therapies (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These data indicate that GLP-1 RAs function primarily as direct vascular and systemic disease-modifying agents, operating through anti-inflammatory pathways and endothelial stabilization, rather than solely through adiposity reduction [85,87].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [85]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [85]
The cited source says what the claim attributes to it.
In the citing paper
“The analysis suggested that the cardiovascular benefit was not fully explained by the magnitude of total weight loss achieved: reductions in waist circumference mediated only approximately one-third of the treatment effect.”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [85]
The cited source says what the claim attributes to it.
In the citing paper
“Although mediation analysis cannot prove complete causal independence from adiposity, these data indicate that an important component of the cardiovascular benefit operates through pathways beyond weight loss alone [85,86].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [85]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Self-citationGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Self-citationSubcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961
Fox, C. S., Massaro, J. M., Hoffmann, U., Pou, K. M., Maurovich-Horvat, P., Liu, C.-Y., Vasan, R. S., Murabito, J. M., Meigs, J. B., Cupples, L. A., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.675355 · Cited by 2,882
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Self-citationBody-Mass Index in 2.3 Million Adolescents and Cardiovascular Death in Adulthood
Twig, G., Yaniv, G., Levine, H., Leiba, A., Goldberger, N., Derazne, E., Ben-Ami Shor, D., Tzur, D., Afek, A., Shamiss, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1503840 · Cited by 1,003
Klein, S., Burke, L. E., Bray, G. A., Blair, S., Allison, D. B., Pi-Sunyer, X., Hong, Y., & Eckel, R. H. (2004) · Circulation · doi:10.1161/01.cir.0000145546.97738.1e · Cited by 934
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404881 · Cited by 871
Cited by
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 81
GLP-1 physiology and pharmacology along the gut-brain axis
Beutler, L. R. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194744 · Cited by 35
Are GLP-1s the first longevity drugs?
(2025) · Nature Biotechnology · doi:10.1038/s41587-025-02932-1 · Cited by 17
Wilson, L., Zhao, Z., Divino, V. M., Bassan, M., Hartaigh, B. Ó., Stensen, S., & Özer, K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70436 · Cited by 22
Self-citationBody Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists
Wang, Z., Wang, L., Zhang, X., Lowery, B. D., Shaffer, L. L., Chen, Y., Wells, Q. S., Flynn, C. R., Williams, B., Spann, M. D., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.53323 · Cited by 25
Metadata
- Authors
- Deanfield, J., Lincoff, A. M., Kahn, S. E., Emerson, S. S., Lingvay, I., Scirica, B. M., Plutzky, J., Kushner, R. F., Colhoun, H. M., Hovingh, G. K., Stensen, S., Weeke, P. E., Jeppesen, O. K., Bravo, R., Wu, C.-C., Komuro, I., Santini, F., Hjelmesæth, J., Urina-Triana, M., Buscemi, S., & Ryan, D. H.
- Affiliations
- University College London (GB)
- Cleveland Clinic (US)
- University of Washington (US)
- The University of Texas Southwestern Medical Center (US)
- Brigham and Women's Hospital (US)
- Northwestern University (US)
- Institute of Genetics and Cancer (GB)
- Novo Nordisk (Denmark) (DK)
- National Taiwan University Hospital (TW)
- International University of Health and Welfare (JP)
- Azienda Ospedaliera Universitaria Pisana (IT)
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
- Pennington Biomedical Research Center (US)
- Corresponding author
- Deanfield, John
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2025-11
- Volume
- 406
- Issue
- 10516
- Pages
- 2257-2268
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4415447839
- Cited by
- 143
- References
- 24
- Citations by year
- 2026: 137 · 2025: 6
- FWCI
- 96.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- semaglutide, major adverse cardiovascular events, adiposity, waist circumference, body weight, obesity, overweight, GLP-1 receptor agonists, SELECT trial, cardiovascular risk stratification
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Male, Middle Aged, Obesity, Body Mass Index, Treatment Outcome, Adiposity, Overweight, Glucagon-Like Peptide 1, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. https://app.cochat.ai/papers/10.1016/s0140-6736(25)01375-3
- The paper
- Deanfield, J., Lincoff, A. M., Kahn, S. E., Emerson, S. S., Lingvay, I., Scirica, B. M., Plutzky, J., Kushner, R. F., Colhoun, H. M., Hovingh, G. K., Stensen, S., Weeke, P. E., Jeppesen, O. K., Bravo, R., Wu, C.-C., Komuro, I., Santini, F., Hjelmesæth, J., Urina-Triana, M., . . . Ryan, D. H. (2025). Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. The Lancet. https://doi.org/10.1016/s0140-6736(25)01375-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.